GI Innovation doses 1st patient in prostate cancer trial with J&J's pasritamig

Coverage, in order

1. 6d ago
   Korea Biomedical Review South Korea obscure study

   GI Innovation doses 1st patient in prostate cancer trial with J&J's pasritamig

   GI Innovation said Thursday that it has dosed the first patient in a global phase 1b/2 clinical trial evaluating its immuno-oncology candidate GI-102 in combination with Johnson & Johnson's experimental cancer drug pasritamig, a first-in-class KLK2xCD3 T-cell engager, in patients with metastatic cas

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.